Jane Street Group, LLC Ligand Pharmaceuticals Inc Transaction History

Jane Street Group, LLC

  • $616 Billion
  • Q3 2025

A detailed history of Jane Street Group, LLC transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Jane Street Group, LLC holds 51,859 shares of LGND stock, worth $10.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
51,859
Previous 5,397 860.89%
Holding current value
$10.4 Million
Previous $613,000 1398.53%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 13, 2025
BUY
$112.56 - $177.14 $5.23 Million - $8.23 Million
46,462 Added 860.89%
51,859 $9.19 Million
Q2 2025

Aug 14, 2025
SELL
$96.67 - $118.22 $3.05 Million - $3.73 Million
-31,525 Reduced 85.38%
5,397 $613,000
Q1 2025

May 14, 2025
BUY
$105.14 - $122.23 $2.48 Million - $2.88 Million
23,553 Added 176.18%
36,922 $3.88 Million
Q4 2024

Feb 14, 2025
SELL
$99.95 - $129.9 $108,245 - $140,681
-1,083 Reduced 7.49%
13,369 $1.43 Million
Q3 2024

Nov 14, 2024
SELL
$82.7 - $110.11 $644,233 - $857,756
-7,790 Reduced 35.02%
14,452 $1.45 Million
Q2 2024

Aug 14, 2024
BUY
$68.53 - $87.91 $222,379 - $285,267
3,245 Added 17.08%
22,242 $1.87 Million
Q1 2024

May 15, 2024
BUY
$68.64 - $89.2 $1.06 Million - $1.38 Million
15,463 Added 437.55%
18,997 $1.39 Million
Q4 2023

Feb 14, 2024
SELL
$49.57 - $72.63 $638,610 - $935,692
-12,883 Reduced 78.47%
3,534 $252,000
Q3 2023

Nov 14, 2023
BUY
$58.86 - $72.67 $659,173 - $813,831
11,199 Added 214.62%
16,417 $983,000
Q2 2023

Aug 14, 2023
SELL
$69.53 - $79.33 $104,920 - $119,708
-1,509 Reduced 22.43%
5,218 $376,000
Q1 2023

May 15, 2023
BUY
$65.67 - $77.08 $441,762 - $518,517
6,727 New
6,727 $494,000
Q3 2022

Nov 14, 2022
BUY
$0.01 - $107.56 $136 - $1.47 Million
13,665 New
13,665 $1.18 Million
Q3 2022

Nov 14, 2022
BUY
$0.01 - $107.56 $136 - $1.47 Million
13,665 New
13,665 $1.18 Million
Q4 2021

Feb 15, 2022
BUY
$127.69 - $165.85 $946,693 - $1.23 Million
7,414 Added 169.19%
11,796 $1.82 Million
Q3 2021

Nov 16, 2021
BUY
$102.33 - $144.73 $167,923 - $237,501
1,641 Added 59.87%
4,382 $611,000
Q2 2021

Aug 16, 2021
SELL
$113.03 - $155.64 $3.59 Million - $4.94 Million
-31,771 Reduced 92.06%
2,741 $360,000
Q1 2021

May 18, 2021
BUY
$99.52 - $215.83 $2.52 Million - $5.45 Million
25,274 Added 273.59%
34,512 $5.26 Million
Q4 2020

Feb 17, 2021
SELL
$80.55 - $106.05 $2 Million - $2.63 Million
-24,777 Reduced 72.84%
9,238 $919,000
Q3 2020

Nov 17, 2020
BUY
$89.56 - $126.72 $1.47 Million - $2.08 Million
16,433 Added 93.46%
34,015 $3.24 Million
Q2 2020

Aug 17, 2020
SELL
$68.28 - $123.65 $394,248 - $713,955
-5,774 Reduced 24.72%
17,582 $1.97 Million
Q4 2019

Feb 14, 2020
BUY
$96.94 - $113.59 $1.81 Million - $2.12 Million
18,673 Added 398.74%
23,356 $2.44 Million
Q3 2019

Nov 14, 2019
SELL
$86.25 - $120.16 $288,420 - $401,815
-3,344 Reduced 41.66%
4,683 $466,000
Q2 2019

Aug 15, 2019
BUY
$107.38 - $129.34 $554,617 - $668,041
5,165 Added 180.47%
8,027 $916,000
Q1 2019

May 16, 2019
SELL
$105.93 - $142.47 $1.64 Million - $2.2 Million
-15,448 Reduced 84.37%
2,862 $360,000
Q4 2018

Feb 15, 2019
BUY
$128.36 - $272.13 $1.45 Million - $3.08 Million
11,300 Added 161.2%
18,310 $2.48 Million
Q3 2018

Nov 14, 2018
BUY
$211.18 - $274.49 $1.11 Million - $1.44 Million
5,233 Added 294.49%
7,010 $1.92 Million
Q2 2018

Aug 15, 2018
BUY
$150.77 - $207.98 $17,790 - $24,541
118 Added 7.11%
1,777 $368,000
Q1 2018

May 15, 2018
BUY
$138.63 - $182.62 $229,987 - $302,966
1,659 New
1,659 $274,000

Others Institutions Holding LGND

# of Institutions
343
Shares Held
20.5M
Call Options Held
19K
Put Options Held
11.5K
View Full List

About LIGAND PHARMACEUTICALS INC

LGND Quotes by TradingView
  • Ticker LGND
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 16,882,800
  • Market Cap $3.39B
  • Description
  • Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...
More about LGND
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email